News
Novo Nordisk’s CEO to step down as weight loss market share plummets
Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and Mounjaro for weight loss and T2D.
2don MSN
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to ...
Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...
Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...
The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback